bosutinib
Sign in to saveAlso known as Bosulif®, SK 606, SK-606, SKI 606, SKI-606, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile
Bosutinib, sold under the brand name Bosulif, is a small molecule BCR-ABL and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukemia.
Research
936 papers- Bosutinib.2012
- A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.Blood · 2021
- Bosutinib.2006
- Bosutinib: Pediatric First Approval.Paediatric drugs · 2024
- Bosutinib.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2010
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 529.165
- Has use
- medication
Show 6 more facts
- chemical formula
- C₂₆H₂₉Cl₂N₅O₃
- canonical SMILES
- CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC
- NCI Thesaurus ID
- C60809
- medical condition treated
- leukemia
- Commons category
- Bosutinib
- significant drug interaction
- idelalisib
via Wikidata · CC0
~2 min read
Encyclopedic overview
7 sectionsContents
- Mechanism
- Medical uses
- Contraindications
- Interactions
- Notes
- See also
- References
Bosutinib, sold under the brand name Bosulif, is a small molecule BCR-ABL and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukemia.
Originally synthesized by Wyeth, it is being developed by Pfizer.
Excerpted from Wikipedia’s “bosutinib” article, available under the CC BY-SA 4.0 licence.